Financial Data and Key Metrics Changes - Total revenues grew by 30% in Q3 2025 compared to the same quarter last year, reaching $97.3 million [2][19] - Operating profit increased to $15.8 million, nearly four times last year's result [2][19] - Operating cash flow was $32 million, restoring cash position to levels seen at the end of 2024 [2][19] - Gross profit grew by 33% to $90.2 million, resulting in a gross margin of 93% compared to 91% in the same quarter of 2024 [19][63] Business Line Data and Key Metrics Changes - Ruconest revenue increased by 29% year-on-year to $82 million, driven by new prescribers and patient enrollments [3][7] - Joenja's revenue grew by 35% year-on-year, generating $15.1 million, with a 25% increase in patients on treatment [3][11] - The company anticipates adding new growth sources for Joenja with pediatric indications and geographic expansion [3][12] Market Data and Key Metrics Changes - The company upgraded its full-year 2025 revenue guidance to $360-$365 million from the previous $335-$350 million [4][21] - The strong performance in Q3 reflects a solid foundation for growth, transitioning from a single-asset company to a biotech with two high-growth products [4][5] Company Strategy and Development Direction - The company aims to optimize capital deployment towards high-growth initiatives and enhance financial discipline [4][25] - Pharming is focused on building a leading global rare disease company, leveraging its strong capabilities in rare diseases [5][24] - The company is advancing its pipeline with two programs that have over $1 billion sales potential each [5][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth prospects of Ruconest, emphasizing its unique value for severe HAE patients [9][24] - The anticipated pediatric launch of Joenja is expected to be a significant growth driver, with preparations on track for a January 2026 approval [12][24] - Management highlighted the importance of maintaining financial discipline and ensuring efficient capital allocation [25][21] Other Important Information - The company is taking steps to reduce G&A headcounts to optimize capital deployment [4] - The recent publication in Cell suggests a higher prevalence of APDS, potentially expanding the patient population significantly [15][16] Q&A Session Summary Question: Impact of new oral therapy on Ruconest and revenue from pediatric patients on Joenja - Management does not see Ruconest competing with sebetralstat, as it serves a different patient population with more severe needs [28][29] - For Joenja, a significant number of pediatric patients identified are expected to convert to therapy quickly after approval [29] Question: Timeline for Ruconest withdrawal outside the US and competitive threats - The withdrawal is planned for the first half of next year, driven by financial sustainability concerns [36] - Management believes Ruconest serves a unique patient population and does not anticipate significant competitive threats [37] Question: Revenue guidance uplift and contributions from Ruconest and Joenja - The revenue guidance uplift is attributed to strong performances from both Ruconest and Joenja, with expectations for continued growth [54][55] Question: Capital allocation priorities and M&A plans - The company is focused on disciplined capital allocation and is not in a rush for M&A, looking for value-accretive opportunities [44][45] Question: Progress on the basket PID trial - The phase two proof-of-concept study is progressing well, with expected readouts in the second half of 2026 [46]

Financial Performance - Total revenues for Q3 2025 increased by 30% to US$97.3 million[13, 43] - RUCONEST® revenues in Q3 2025 reached US$82.2 million[13, 22] - Joenja® revenues in Q3 2025 amounted to US$15.1 million[13, 27] - Operating profit significantly grew to US$16.0 million in Q3 2025[13, 43] - Cash flow from operations was US$32 million in Q3 2025[14, 41] - Total revenues for 9M 2025 grew 33% to US$269.6 million[44, 45] Business Updates and Outlook - 2025 revenue guidance raised to US$365-375 million due to strong RUCONEST® performance[14, 51] - RUCONEST® U S volume growth was +24% in 3Q25 and +28% in 9M25[22] - There are 116 US patients on Joenja® representing a +25% increase vs 3Q24[27] - FDA filing for Leniolisib for 4-11 year old APDS patients is based on Phase III data and has a PDUFA date of Jan 31, 2026[28]

For the Month of November 2025 Commission File Number: 001-39822 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of ...

Core Insights - Pharming Group N.V. reported a strong financial performance for Q3 2025, with total revenues increasing by 30% to US$97.3 million compared to Q3 2024, driven by growth in both RUCONEST® and Joenja® [9][30][31] Financial Performance - Total revenues for Q3 2025 reached US$97.3 million, a 30% increase from US$74.8 million in Q3 2024 [30] - RUCONEST® revenue increased by 29% to US$82.2 million, reflecting sustained growth in patients and prescribers [9][10] - Joenja® revenue grew by 35% to US$15.1 million, driven by a significant increase in patients on paid therapy [13][31] - Operating profit surged by 285% to US$15.8 million compared to US$4.1 million in Q3 2024 [32] - The company generated US$32 million in cash flow from operations during the quarter [34] Strategic Developments - Pharming announced a significant reduction in general and administrative headcount to optimize capital deployment towards high-growth initiatives [5][23] - The company is focusing on expanding its pipeline, particularly for leniolisib in broader primary immunodeficiency populations and addressing unmet needs in primary mitochondrial disease with KL1333 [4][5] Market Position and Outlook - The company raised its full-year revenue guidance to between US$365 million and US$375 million, up from the previous range of US$335 million to US$350 million [6][44] - The U.S. market contributed 89% of Q3 revenue, while the EU and Rest of World contributed 11% [14] - Pharming plans to launch a pediatric formulation of leniolisib for children aged 4 to 11 years, with FDA priority review expected by January 2026 [20][44] Organizational Changes - Leverne Marsh has been appointed as Chief Commercial Officer, effective January 1, 2026, succeeding Stephen Toor [7][24] - Kenneth Lynard was appointed as Chief Financial Officer, effective October 1, 2025, enhancing the company's financial leadership [22] Corporate Highlights - Pharming was promoted from the Euronext AScX® to the AMX® index, reflecting its growing market capitalization and trading activity [25] - The company is working on options to mitigate the impact of recently announced U.S. tariffs, although it does not expect a material impact on its business [26]

Core Insights - Pharming Group N.V. will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025 [1] - CEO Fabrice Chouraqui will engage in a Fireside Chat Q&A session on November 19 at 10:00 GMT/11:00 CET [2] - Pharming is a global biopharmaceutical company focused on developing innovative medicines for rare and life-threatening diseases [3] Company Information - Pharming is headquartered in Leiden, the Netherlands, with a significant number of employees based in the U.S. [3] - The company is dedicated to transforming the lives of patients through a portfolio of small molecules and biologics [3] Contact Information - Investor Relations can be reached at investor@pharming.com for inquiries regarding the conference or to schedule meetings [2][5] - Media Relations contacts include Saskia Mehring for global inquiries and Ethan Metelenis for U.S. inquiries [5]

Core Insights - Pharming Group N.V. will report its preliminary (unaudited) financial results for the third quarter of 2025 on November 6, 2025, along with a business update [1] - A conference call and webcast for analysts and investors will take place on the same day at 13:30 CET/07:30 am ET [1] Conference Call Details - Participants must register in advance to join the conference call or watch the live webcast [2] - Registration for the conference call can be done through a provided link, after which dial-in information and a unique PIN will be sent to attendees [3] - The webcast will also be available on the Pharming website, with a replay accessible shortly after the event [4] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare and life-threatening diseases [5] - The company is headquartered in Leiden, the Netherlands, with a significant number of employees based in the U.S. [5]

Core Insights - Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the ACAAI 2025 Annual Scientific Meeting, highlighting the company's commitment to advancing research in hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [1][3]. Summary by Category Clinical Data - Five posters will present positive clinical, economic, and comparative data for RUCONEST® in the treatment of on-demand hereditary angioedema (HAE) [2]. - Seven posters will focus on the real-world effectiveness of Joenja® (leniolisib), including results from the Phase III pediatric trial and insights into the burden faced by pediatric patients and caregivers dealing with APDS [2]. Presentation Details - Specific studies include an indirect treatment comparison of recombinant C1 inhibitor and Sebetralstat for HAE on-demand therapy, cost-effectiveness analysis, and patient-reported outcome measures across clinical trials [4][5]. - The presentations are scheduled for various dates and times during the ACAAI meeting, with ePosters accessible online for registered attendees [5]. Company Overview - Pharming Group is a biopharmaceutical company focused on developing innovative medicines for rare diseases, with a significant presence in both the U.S. and Europe [14].

Core Insights - Pharming Group N.V. is implementing an organizational restructuring to accelerate growth and optimize capital allocation by reducing general and administrative expenses [1][2] Restructuring Details - The restructuring involves a redesign of the organizational structure and a 20% net reduction in non-commercial and non-medical headcount, primarily at the Netherlands headquarters [2] - The company aims to reduce total G&A expenses by 15%, equating to approximately US$10 million annually, with one-time restructuring costs expected to be around $7 million in Q4 2025 [2] Consultation Process - Pharming has engaged with its Dutch Works Council over the past several months to discuss the organizational changes in compliance with Dutch labor law [3] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare and life-threatening diseases [4]

Core Viewpoint - Pharming Group N.V. announced that the FDA has accepted its supplemental New Drug Application for leniolisib, aimed at treating children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), with a target action date of January 31, 2026 [1][7]. Group 1: FDA Approval Process - The supplemental New Drug Application is based on positive results from a Phase III study showing improvements in lymphadenopathy and naïve B cells over 12 weeks [2]. - The FDA has granted Priority Review status to the application, indicating that the treatment could offer significant improvements in effectiveness or safety for serious conditions [3]. Group 2: Disease Background - APDS is a rare primary immunodeficiency characterized by immune dysregulation and recurrent infections, often leading to severe complications such as lung damage and lymphoma [5]. - The condition affects approximately 1 to 2 individuals per million globally, and patients often experience a median diagnostic delay of 7 years [5]. Group 3: Treatment Details - Leniolisib is an oral PI3Kδ inhibitor, previously approved for patients aged 12 and older, and is the first targeted treatment for APDS [6][4]. - The drug has shown statistically significant improvements in clinical trials, and its safety and tolerability have been supported by long-term data [6]. Group 4: Future Developments - Leniolisib is currently under regulatory review in multiple regions, including the European Economic Area, Japan, and Canada, for its use in APDS [6]. - The company is also evaluating leniolisib in additional clinical trials for other primary immunodeficiencies with immune dysregulation [8].

Core Insights - U.S. stock futures showed mixed results, with Dow futures up approximately 0.1% on Friday [1] - Concentrix Corporation reported disappointing third-quarter adjusted EPS results and lowered its FY25 adjusted EPS guidance, leading to a significant drop in its share price [1][2] Concentrix Corporation - Concentrix reported quarterly earnings of $2.78 per share, missing the Street estimate of $2.86 [2] - Quarterly revenue was $2.48 billion, surpassing the analyst consensus estimate of $2.45 billion [2] - The company reduced its fiscal 2025 adjusted EPS guidance to a range of $11.11 to $11.23, below the previous estimate of $11.69 [2] - Concentrix raised its revenue outlook for FY25 to between $9.79 billion and $9.82 billion, compared to the prior estimate of $9.77 billion [2] - Shares of Concentrix fell 20.5% to $43.73 in pre-market trading following the earnings report [2] Other Stocks - DarioHealth Corp. saw a decline of 18.9% to $11.10 in pre-market trading after a significant increase the previous day [5] - Legacy Education Inc. dropped 13.3% to $10.68 after reporting worse-than-expected fourth-quarter EPS results [5] - Apellis Pharmaceuticals, Inc. decreased by 9.5% to $20.12 in pre-market trading [5] - Pharming Group N.V. fell 9.1% to $13.45, while Kingsoft Cloud Holdings Limited declined 7.5% to $16.15 after announcing a new share offering [5] - Other notable declines included IREN Limited down 7.4% to $42.85 and LuxExperience B.V. down 6.3% to $7.89 [5]